Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

ClinicalTrials.gov ID: NCT03627767

Public ClinicalTrials.gov record NCT03627767. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. Subjects responding well to an initial open-label 12 week treatment of PF-04965842 (200 mg) taken orally once daily (QD) will be identified and randomized in a double-blind manner to receive 200 mg QD PF-04965842, 100 mg QD PF-04965842, or QD placebo. Efficacy and safety of 2 doses of PF-04965842 will be evaluated relative to placebo over 40 weeks. Subjects experiencing significant worsening of their symptoms, i.e., protocol-defined flare, enter 12 weeks rescue treatment and receive 200 mg PF-04965842 together with a marketed topical medicine. Eligible patients will have the option to enter a long-term extension study after completing the initial 12 week treatment, the 12 week rescue treatment, and the 40 week blinded treatment.

Study identification

NCT ID
NCT03627767
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
1,235 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 10, 2018
Primary completion
Sep 1, 2020
Completion
Oct 6, 2020
Last update posted
Sep 19, 2021

2018 – 2020

United States locations

U.S. sites
52
U.S. states
22
U.S. cities
47
Facility City State ZIP Site status
Total Skin and Beauty Dermatology Center, PC Birmingham Alabama 35205
University of Alabama at Birmingham, Dermatology at the Whitaker Clinic Birmingham Alabama 35233
Clinical Research Center of Alabama, LLC Birmingham Alabama 35244
Tien Q Nguyen MD Inc dba First OC Dermatology Fountain Valley California 92708
Center for Dermatology Clinical Research, Inc. Fremont California 94538
Beach Allergy and Asthma Specialty Group, A Medical Corporation Long Beach California 90808
Dermatology Specialists, Inc. Oceanside California 92056
University of California San Diego San Diego California 92122
San Luis Dermatology and Laser Clinic San Luis Obispo California 93405
Southern California Dermatology, Inc. Santa Ana California 92701
Mosaic Dermatology Santa Monica California 90403
Bay Pines VAHCS Bay Pines Florida 33744
Skin Care Research, LLC Boca Raton Florida 33486
Skin Research Institute Coral Gables Florida 33146
Baumann Cosmetic and Research Institute Miami Florida 33137
Park Avenue Dermatology Orange Park Florida 32073
USF Asthma, Allergy & Immunology Clinical Research Unit Tampa Florida 33613
Emory University Atlanta Georgia 30322
Dermatologic Surgery Specialists, PC Macon Georgia 31217
Midwest Allergy Sinus Asthma, SC Normal Illinois 61761
NorthShore University HealthSystem Dermatology Clinical Trials Unit Skokie Illinois 60077
Dawes Fretzin Clinical Research Group, LLC Indianapolis Indiana 46250
Ds Research New Albany Indiana 47150
The Indiana Clinical Trials Center Plainfield Indiana 46168
Kansas City Dermatology, P.A. Overland Park Kansas 66215
DXP Imaging Louisville Kentucky 40216
Skin Sciences PLLC Louisville Kentucky 40217
Qualmedica Research, LLC Owensboro Kentucky 42301
Owensboro Dermatology Associates Owensboro Kentucky 42303
Meridian Clinical Research, LLC Baton Rouge Louisiana 70808
Tulane University Health Sciences Center New Orleans Louisiana 70112
Tufts Medical Center Boston Massachusetts 02111
Mayo Clinic Rochester Minnesota 55905
MediSearch Clinical Trials Saint Joseph Missouri 64506
Saint Louis University Dermatology St Louis Missouri 63104
Forest Hills Dermatology Group Kew Gardens New York 11374
Juva Skin and Laser Center New York New York 10022
UR Dermatology at College Town Rochester New York 14620
M3 - Wake Research, Inc. Raleigh North Carolina 27612
Bexley Dermatology Research Bexley Ohio 43209
Lynn Health Science Institute Oklahoma City Oklahoma 73112
Newton Clinical Research Oklahoma City Oklahoma 73120
Oregon Medical Research Center Portland Oregon 97223
Paddington Testing Co, Inc. Philadelphia Pennsylvania 19103
Health Concepts Rapid City South Dakota 57702
Dermatology Treatment & Research Center, PA Dallas Texas 75230
Innovate Research, LLC Fort Worth Texas 76244
The University of Texas Health Science Center Houston Houston Texas 77030
Ventavia Research Group Hurst Hurst Texas 76054
Virginia Clinical Research, Inc Norfolk Virginia 23502
Dermatology Associates of Seattle Seattle Washington 98101
Dermatology Specialists of Spokane Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 183 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03627767, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 19, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03627767 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →